+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Exosome Drug Market Report and Forecast 2023-2031

  • PDF Icon


  • 147 Pages
  • April 2023
  • Region: Global
  • Expert Market Research
  • ID: 5780664
The global exosome drug market size attained a value of USD 21.949 million in 2022. The market is likely to grow at a CAGR of 6.55% during the forecast period of 2023-2031 to attain a value of USD 38.85 million by 2031.

Exosome Drug Market: Introduction

Exosomes are small extracellular vesicles secreted by various cells and are involved in intercellular communication. They play a critical role in the maintenance of cellular homeostasis and are being increasingly recognized as potential drug delivery vehicles for the treatment of various diseases. The report covers the market for exosomes drugs and provides a detailed analysis of the market size, growth, and trends. The global exosomes drug market is highly competitive, with several key players operating in the space. The key players in the market are expected to focus on research and development activities to develop innovative products and gain a competitive edge.

Exosome Drug - Application and Uses

Exosomes have been identified as potential therapeutic agents for a range of diseases, including cancer, neurological disorders, cardiovascular diseases, and inflammatory disorders. The prevalence of these diseases is increasing globally, which is expected to drive the demand for exosome-based therapies.

Cancer is one of the leading causes of death worldwide, with approximately 10 million deaths per year. The rising prevalence of cancer is expected to drive the growth of the exosome drug market. According to the World Health Organization (WHO), cancer is the second leading cause of death globally and was responsible for an estimated 9.6 million deaths in 2018. The WHO also estimates that the number of new cancer cases will rise by about 70% over the next two decades.

Neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease, are also on the rise globally, driven by aging populations and changing lifestyles. According to the World Alzheimer Report, there were an estimated 50 million people living with dementia in 2018, and this number is expected to triple by 2050. The rising prevalence of neurodegenerative disorders is expected to drive the demand for exosome-based therapies.

Cardiovascular diseases, such as heart disease and stroke, are a leading cause of death globally, accounting for an estimated 17.9 million deaths in 2019. The rising prevalence of cardiovascular diseases is expected to drive the growth of the exosome drug market.

Inflammatory disorders, such as rheumatoid arthritis and inflammatory bowel disease, are also on the rise globally, driven by changing lifestyles and environmental factors. According to the Centers for Disease Control and Prevention (CDC), an estimated 54.4 million adults in the United States have been diagnosed with arthritis, and this number is expected to rise to 78.4 million by 2040. The rising prevalence of inflammatory disorders is expected to drive the demand for exosome-based therapies.

Exosome Drug Market Segmentations

The market can be categorized into biomolecule type, product type, application, disease type, and region.

Market Breakup by Biomolecule Type

  • Non-Coding RNAs
  • mRNA (exoRNA)
  • Proteins/ Peptides
  • DNA Fragments
  • Lipids

Market Breakup by Product Type

  • Kits
  • Reagents
  • Instruments

Market Breakup by Application

  • Biomarkers
  • Drug Delivery System
  • Vaccine Development
  • Therapeutic Agents
  • Others

Market Breakup by Disease Type

  • Cancer Disease
  • Cardiovascular Disease
  • Neurodegenerative Disease
  • Tissue Regeneration
  • Infectious Disease
  • Others

Exosome Drug Market Breakup by Region

North America

  • United States of America
  • Canada


  • United Kingdom
  • Germany
  • France
  • Italy
  • Others

Asia Pacific

  • China
  • Japan
  • India
  • Australia
  • Others

Latin America

  • Brazil
  • Argentina
  • Mexico
  • Others

Middle East and Africa

  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Exosome Drug Market Scenario

North America dominates the exosomes drug market, followed by Europe and the Asia Pacific. The high prevalence of cancer and neurodegenerative diseases in North America, coupled with the availability of advanced healthcare infrastructure and increasing investment in research and development activities, is driving the growth of the market in the region. Europe is also a significant market for exosome drugs, with the presence of key players and increasing investment in research and development activities. The Asia Pacific region is expected to grow at the highest CAGR during the forecast period, owing to the increasing prevalence of chronic diseases and rising healthcare expenditure.

However, the market growth may be hindered by factors such as the high cost of exosome-based therapies, regulatory challenges, and the lack of standardized isolation and purification methods. In addition, the limited understanding of exosome biology and the complexity of exosome-based therapies may also impede the market growth.

Key Players in the Global Exosome Drug Market

The report gives an in-depth analysis of the key players involved in the Exosome Drug market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
  • Danaher Corporation (Beckman Coulter Inc.)
  • Hologic Inc
  • Lonza Group AG
  • Fujifilm Holdings Corporation
  • Miltenyi Biotec GmbH
  • Qiagen N.V
  • Thermo Fisher Scientific Inc
  • JSR Corporation (MBL International)
  • Illumina, Inc
  • Takara Bio Inc
  • Malvern Instruments Ltd. (Spectris Plc Company)
  • Abcam Plc
  • Ampersand Capital Partner (New England Peptide, Inc.)
  • Evox Therapeutics Ltd

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
2 Research Methodology3 Executive Summary
4 Exosomes Drug Overview
4.1 Drug Overview
4.1.1 Pharmacodynamics
4.1.2 Pharmacokinetics
4.1.3 Adverse Events
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Global Exosomes Drug Market
6.1 Global Exosomes Drug Market Overview
6.2 Global Exosomes Drug Market Analysis
6.2.1 Market Overview Global Exosomes Drug Market Historical Value (2016-2022) Global Exosomes Drug Market Forecast Value (2023-2031)
6.3 Global Exosomes Drug Market by Biomolecule Type
6.3.1 Market Overview Non-Coding RNAs mRNA (exoRNA) Proteins/Peptides DNA Fragments Lipids
6.4 Global Exosomes Drug Market by Product Type
6.4.1 Market Overview Kits Reagents Instruments
6.5 Global Exosomes Drug Market by Application
6.5.1 Market Overview Biomarkers Drug Delivery System Vaccine Development Therapeutic Agents Others
6.6 Global Exosomes Drug Market by Disease Type
6.6.1 Market Overview Cancer Disease Neurodegenerative Diseases Cardiovascular Diseases Infectious Diseases Tissue Regeneration Others
6.7 Global Exosomes Drug Market by Region
6.7.1 Market Overview North America Europe Asia Pacific Latin America Middle East and Africa
7 North America Exosomes Drug Treatment Market
7.1 Market Share by Country
7.2 United States of America
7.2.1 Historical Trend (2016-2022)
7.2.2 Forecast Trend (2023-2031)
7.3 Canada
7.3.1 Historical Trend (2016-2022)
7.3.2 Forecast Trend (2023-2031)
8 Europe Exosomes Drug Treatment Market
8.1 Market Share by Country
8.2 United Kingdom
8.2.1 Historical Trend (2016-2022)
8.2.2 Forecast Trend (2023-2031)
8.3 Germany
8.3.1 Historical Trend (2016-2022)
8.3.2 Forecast Trend (2023-2031)
8.4 France
8.4.1 Historical Trend (2016-2022)
8.4.2 Forecast Trend (2023-2031)
8.5 Italy
8.5.1 Historical Trend (2016-2022)
8.5.2 Forecast Trend (2023-2031)
8.6 Others
9 Asia Pacific Exosomes Drug Treatment Market
9.1 Market Share by Country
9.2 China
9.2.1 Historical Trend (2016-2022)
9.2.2 Forecast Trend (2023-2031)
9.3 Japan
9.3.1 Historical Trend (2016-2022)
9.3.2 Forecast Trend (2023-2031)
9.4 India
9.4.1 Historical Trend (2016-2022)
9.4.2 Forecast Trend (2023-2031)
9.5.1 Historical Trend (2016-2022)
9.5.2 Forecast Trend (2023-2031)
9.6 Australia
9.6.1 Historical Trend (2016-2022)
9.6.2 Forecast Trend (2023-2031)
9.7 Others
10 Latin America Exosomes Drug Treatment Market
10.1 Market Share by Country
10.2 Brazil
10.2.1 Historical Trend (2016-2022)
10.2.2 Forecast Trend (2023-2031)
10.3 Argentina
10.3.1 Historical Trend (2016-2022)
10.3.2 Forecast Trend (2023-2031)
10.4 Mexico
10.4.1 Historical Trend (2016-2022)
10.4.2 Forecast Trend (2023-2031)
10.5 Others
11 Middle East and Africa Exosomes Drug Treatment Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.2.1 Historical Trend (2016-2022)
11.2.2 Forecast Trend (2023-2031)
11.3 United Arab Emirates
11.3.1 Historical Trend (2016-2022)
11.3.2 Forecast Trend (2023-2031)
11.4 Nigeria
11.4.1 Historical Trend (2016-2022)
11.4.2 Forecast Trend (2023-2031)
11.5 South Africa
11.5.1 Historical Trend (2016-2022)
11.5.2 Forecast Trend (2023-2031)
11.6 Others
12 Current Scenario Evaluation and Regulatory Framework
12.1 Emerging Therapies and Clinical Trials Synopsis
12.2 Patent Landscape
12.2.1 Patent Overview Patent Status and Expiry Timelines from Drug Development to Commercial Launch New Drug Application Documentation and Approval Process
12.3 Cost of Treatment
12.4 Investment Scenarios
12.5 Regulatory Framework
12.5.1 Regulatory Overview US FDA EU EMA INDIA CDSCO JAPAN PMDA Others
13 Challenges and Unmet Need
13.1 Treatment Pathway Challenges
13.2 Compliance and Drop-Out Rate
13.3 Awareness and Prevention Gaps
14 Global Exosomes Drug Market Dynamics
14.1 Market Drivers and Constraints
14.2 SWOT Analysis
14.3 Drug Adoption Parameters
14.4 Porter’s Five Forces Model
14.5 Key Demand Indicators
14.6 Key Price Indicators
14.7 Value Chain Analysis
15 Supplier Landscape
15.1 Danaher Corporation (Beckman Coulter Inc.)
15.1.1 Company Overview
15.1.2 Product Portfolio
15.1.3 Demographic Reach and Achievements
15.1.4 Mergers and Acquisitions
15.1.5 Certifications
15.2 Hologic Inc.
15.2.1 Company Overview
15.2.2 Product portfolio
15.2.3 Demographic Reach and Achievements
15.2.4 Mergers and Acquisitions
15.2.5 Certifications
15.3 Lonza Group AG
15.3.1 Company Overview
15.3.2 Product portfolio
15.3.3 Demographic Reach and Achievements
15.3.4 Mergers and Acquisitions
15.3.5 Certifications
15.4 Fujifilm Holdings Corporation
15.4.1 Company Overview
15.4.2 Product portfolio
15.4.3 Demographic Reach and Achievements
15.4.4 Mergers and Acquisitions
15.4.5 Certifications
15.5 Miltenyi Biotec GmbH
15.5.1 Company Overview
15.5.2 Product portfolio
15.5.3 Demographic Reach and Achievements
15.5.4 Mergers and Acquisitions
15.5.5 Certifications
15.6 Qiagen N.V.
15.6.1 Company Overview
15.6.2 Product portfolio
15.6.3 Demographic Reach and Achievements
15.6.4 Mergers and Acquisitions
15.6.5 Certifications
15.7 Thermo Fisher Scientific Inc.
15.7.1 Company Overview
15.7.2 Product portfolio
15.7.3 Demographic Reach and Achievements
15.7.4 Mergers and Acquisitions
15.7.5 Certifications
15.8 JSR Corporation (MBL International)
15.8.1 Company Overview
15.8.2 Product portfolio
15.8.3 Demographic Reach and Achievements
15.8.4 Mergers and Acquisitions
15.8.5 Certifications
15.9 Illumina, Inc.
15.9.1 Company Overview
15.9.2 Product portfolio
15.9.3 Demographic Reach and Achievements
15.9.4 Mergers and Acquisitions
15.9.5 Certifications
15.10 Takara Bio Inc.
15.10.1 Company Overview
15.10.2 Product portfolio
15.10.3 Demographic Reach and Achievements
15.10.4 Mergers and Acquisitions
15.10.5 Certifications
15.11 Malvern Instruments Ltd. (Spectris Plc Company)
15.11.1 Company Overview
15.11.2 Product portfolio
15.11.3 Demographic Reach and Achievements
15.11.4 Mergers and Acquisitions
15.11.5 Certifications
15.12 Abcam Plc.
15.12.1 Company Overview
15.12.2 Product portfolio
15.12.3 Demographic Reach and Achievements
15.12.4 Mergers and Acquisitions
15.12.5 Certifications
15.13 Ampersand Capital Partner (New England Peptide, Inc.)
15.13.1 Company Overview
15.13.2 Product portfolio
15.13.3 Demographic Reach and Achievements
15.13.4 Mergers and Acquisitions
15.13.5 Certifications
15.14 Evox Therapeutics Ltd.
15.14.1 Company Overview
15.14.2 Product portfolio
15.14.3 Demographic Reach and Achievements
15.14.4 Mergers and Acquisitions
15.14.5 Certifications
16 Pricing Models and Strategies (Additional Insight)
16.1 Cost Model
16.1.1 Manufacturing Cost Analysis
16.1.2 Procurement Cost Analysis
16.2 Pricing Strategies
16.2.1 Competitor Pricing Analysis
16.2.2 Key Assessment of Product Attributes
16.2.3 Pricing Benchmark
17 Global Exosomes Drug Market- Distribution Model (Additional Insight)
17.1 Overview
17.2 Potential Distributors
17.3 Key Parameters for Distribution Partner Assessment

Companies Mentioned

  • Danaher Corporation (Beckman Coulter Inc.)
  • Hologic Inc.
  • Lonza Group AG
  • Fujifilm Holdings Corporation
  • Miltenyi Biotec GmbH
  • Qiagen N.V.
  • Thermo Fisher Scientific Inc.
  • JSR Corporation (MBL International)
  • Illumina, Inc.
  • Takara Bio Inc.
  • Malvern Instruments Ltd. (Spectris Plc Company)
  • Abcam Plc.
  • Ampersand Capital Partner (New England Peptide, Inc.)
  • Evox Therapeutics Ltd.



Table Information